Novo Nordisk Introduces Tiered Pricing for Wegovy in U.S.
Novo Nordisk has announced a tiered pricing structure for its weight-loss drug Wegovy in the U.S. market. Effective January 5, self-paying patients can access lower doses for $149 per month and higher doses for $299 per month. This marks the company's first explicit pricing commitment for Wegovy in the United States.
Insights:
Novo Nordisk A/S , a leading pharmaceutical company based in Denmark 
DK, has unveiled a tiered pricing strategy for its weight-loss medication, Wegovy, in the United States 
US. Effective January 5, the pricing structure offers self-paying patients access to lower doses of 1.5mg and 4mg at $149 per month, while higher doses of 9mg and 25mg are priced at $299 per month. This announcement marks Novo Nordisk's first explicit pricing commitment for Wegovy in the U.S. market, the largest pharmaceutical market globally.
DK, has unveiled a tiered pricing strategy for its weight-loss medication, Wegovy, in the United States US. Effective January 5, the pricing structure offers self-paying patients access to lower doses of 1.5mg and 4mg at $149 per month, while higher doses of 9mg and 25mg are priced at $299 per month. This announcement marks Novo Nordisk's first explicit pricing commitment for Wegovy in the U.S. market, the largest pharmaceutical market globally.
